SGN BB 228
Alternative Names: PF-08046049; PRS-346; SGN-BB 228Latest Information Update: 15 Dec 2023
At a glance
- Originator Pieris Pharmaceuticals
- Developer Seagen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 4-1BB ligand expression stimulants; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma; Solid tumours
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Solid tumors presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 03 Jan 2023 Phase-I clinical trials in Malignant melanoma (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT05571839)